| Value | ₹998.8 Cr |
|---|
NSE filing, NSE: NEPHROPLUS. Summary written from the filing by ALFA Finder's alert engine.
Nephrocare Health Services Ltd: key numbers
- Share price
- ₹624.60
- Market cap
- ₹6,267 Cr
- Revenue (annual)
- ₹998.8 Cr
- Net profit (annual)
- ₹76.84 Cr
- P/E (TTM)
- 73.6×Sector 53.7×
- Promoter holding
- 58.31%-5.54% QoQ
- FII holding
- 11.73%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nephrocare Health Services Ltd
All →Nephrocare Health Services Other Announcement
Nephrocare filed Crisil's monitoring agency report on IPO proceeds for the quarter ended 30 September 2026. The report shows no deviation from the stated objects.
Nephrocare Health Services Investor Presentation: Key Takeaways
H1FY27 revenue ₹585.2 Cr (+23.6% YoY), Adj EBITDA ₹134.4 Cr (+15.3%), Adj PAT ₹76.1 Cr (+34.7%). Expansion via acquisitions in Philippines, Kazakhstan and Saudi Arabia.
Nephrocare Health Services Results Update
Nephrocare Health Services released its Q2 and H1 FY27 results press release. Revenue and adjusted profit grew year-on-year, alongside network expansion into Kazakhstan.
Nephrocare Health Services Q2 FY27 Results: Turns Profitable, Net Profit ₹33.5 Cr
Nephrocare Health Services Ltd reported revenue from operations of ₹303.4 Cr (+23.5% YoY) and net profit of ₹33.5 Cr for Q2 FY27.
- Key figure
- Net profit ₹33.5 Cr
Nephrocare Health Services Legal & Regulatory
Nephrocare's Uzbek subsidiary won a court ruling invalidating a ₹14.79 crore tax demand. The tax department must reconsider the audit, and the decision remains appealable.
- Value
- ₹14.79 Cr
Nephrocare Health Services Acquisition
Nephrocare's Philippines subsidiary agreed to acquire dialysis center assets from JCM Summit Health under an Asset Transfer Agreement. Consideration is undisclosed but the deal exceeds materiality thresholds.
Other results update announcements
All →Multi Commodity Exchange of India Results Update
MCX reported H1FY27 consolidated revenue of ₹1,502 crore, up 100.8% YoY, and PAT of ₹868 crore. Q2FY27 PAT rose 130.8% YoY to ₹455 crore.
Shanti Gold International Results Update
Shanti Gold reported H1 FY27 revenue of Rs. 1,462.3 crore and PAT of Rs. 80.0 crore. Revenue doubled, but Q2 EBITDA margin compressed to 5.7%.
Aarti Drugs Results Update
Aarti Drugs reports Q2 FY27 revenue of ₹828.8 Crore and PAT of ₹82.8 Crore, up 83% YoY. Results reflect record quarterly EBITDA and margin expansion.
Fine Organic Industries Results Update
Fine Organic reports Q2 FY27 revenue of ₹729.4 Crore and PAT of ₹152.1 Crore, up 40.1%. Results show strong year-on-year growth across revenue, EBITDA and profit.
Jyoti Structures Results Update
Jyoti Structures reported standalone Q2 FY27 total income up 60.2% to Rs 248.57 crore and PAT of Rs 15.37 crore. The order book stood at Rs 4,219 crore as of September 30, 2026.
Samhi Hotels Results Update
SAMHI Hotels reported unaudited Q2 and H1 FY27 results, with Q2 total income up 15.6% to Rs 3,427 Mn and PAT of Rs 411 Mn. Management highlighted same-store growth and a pipeline of about 1,700 new rooms through FY2031.